Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

bout the future of this new anticancer drug candidate," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer.  

Side effects were generally manageable with dose-limiting toxicity consisting primarily of Grade 3 diarrhea (20-23%) typically occurring after three months of therapy for both schedules.   Neuropathy and alopecia were minimal with only one patient experiencing G2 alopecia in the study.  Both neuropathy and alopecia are significant adverse events commonly associated with standard breast cancer therapies [Safety Tables, Figures D and E].

NKTR-102 Phase 2 Data Presentation in Metastatic Breast Cancer

  • Awada et. al., Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).Abstract #1034, Poster Board #24Poster Discussion Session:  Breast Cancer - Triple-negative/Cytotoxics/Local Therapy  Session Date and Time:  Saturday, June 4, 2011, 2:00 PM – 6:00 PM, Central TimeLocation:  E450bFigure A: Efficacy Table: Objective Tumor Response Rate by RECIST (Investigator Assessment)Response by RECIST v 1.0NKTR-102145 mg/m2q14d NKTR-102145 mg/m2q21d TOTALN

    31*

    35

    66ORR (confirmed + unconfirmed)

    11 (35%)

    11 (31%)

    22 (33%)ORR (confirmed)

    10 (32%)

    9 (26%)

    19 (29%)CR (confirmed)

    2 (7%)

    0

    2 (3%)PR (confirmed)

    8 (26%)

    9 (26%)

    17 (26%)SD

    12 (39%)

    16 (46%)

    28 (42%)PD

    9 (29%)

    10 (29%)

    19 (29%)Median duration of response

    8.3 months

    4.4 months

    5.8 monthsClinical benefit

    (CR+PR+SD>6 months)

    13 (42%)

    17 (49%)

    30 (46%)Median progression-free survival**

    3.5 months

    5.3 months

    4.6 monthsMedian overall survival**

    8.8 months

    13.1 months

    10.3 months
    '/>"/>


  • SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
    2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
    3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
    5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
    6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
    9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
    10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
    11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ... has fueled rapid growth of these markets. ...
    (Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ... $2.92 per share, net to the seller in cash, ...
    (Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
    Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
    ... JERUSALEM, Israel, June 15 ,The University of Pittsburgh ... announced today that the Institute has joined an elite,group of ... are now,enrolling patients to participate in the ExCell research study. ... assessing the safety and efficacy of StemEx(R), an,investigational product derived ...
    ... , IRVINE, Calif., June 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that ... utility of Masimo PVI as a noninvasive and continuous ... this week at the European Society of Anaesthesiology (ESA) ...
    Cached Medicine Technology:UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 2UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
    (Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
    (Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
    (Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
    (Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
    (Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
    Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
    ... about multiple births dominating the media, it is easy to ... many couples trying to start a family. In fact, more ... number is growing. In the past 10 years the ... billion. Despite the troubled economy, reproductive medicine is thriving, ...
    ... Researchers from Thomas Jefferson University have identified a ... the growth and migration of prostate cancer cells, especially ... the American Journal of Pathology . , They ... the protein when compared to normal prostate cells, according ...
    ... socioeconomic characteristics of people who play state lotteries are similar ... with a small potential for high return, and just like ... invest this way in the stock market, research from The ... "Who Gambles in the Stock Market?" Alok Kumar, assistant professor ...
    ... Zuckerman, M.D., first considered a life in medicine at the ... weekly trials and tribulations of a young television doctor named ... show, it sparked an idea which led to an impressive ... Today, Dr. Zuckerman was named President of the American ...
    ... Healthcare Management Systems, Inc. (R) (HMS) ... Act of 2009 (ARRA) as it unfolds, ... the HIMSS informational webinar yesterday on ARRA, even with ... to wait to implement electronic health record (EHR) technology ...
    ... Consecutive Profitable Quarter Earns $.08 Per Diluted ShareLARGO, ... Bulletin Board: UVICF ; TSX Venture Exchange: ... specialty contact lenses, today reported its operating results ... (FY2009).Net sales, excluding royalty income, increased 1.2% to ...
    Cached Medicine News:Health News:A Recession-Resistant Business? Introducing FertilityAuthority.com 2Health News:Proepithelin encourages cell growth and migration in prostate cancer 2Health News:Investors who 'gamble' in the stock market have same characteristics as lottery players 2Health News:Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons 2Health News:Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons 3Health News:HMS Responds to American Recovery and Reinvestment Act of 2009 2Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 2Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 3Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 4Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 5
    Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
    ... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
    Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
    Bravo pH capsule with delivery system....
    Medicine Products: